For example, a nested case–control study using samples from the United Kingdom Collaborative Trial of Ovarian Cancer Screening trial, including serial samples from women up to 7 years pre-diagnosis, demonstrated that an ELISA-based combined biomarker panel comprised of IGFBP2, LCAT and CA125 outperformed the performance of CA125 alone up to 3 years pre-diagnosis [68]. This evidence concerns the gene LCAT and ovarian carcinoma.